Immunohistochemical Assessment of ER-P31, a Mouse Anti-Oestrogen Receptor Protein Monoclonal Antibody in Human Breast Cancers: Comparison with ER-ICA (Abbott) and Radioligand Assays

Tumor Biology ◽  
1991 ◽  
Vol 12 (1) ◽  
pp. 16-23 ◽  
Author(s):  
S.Y. Wong ◽  
A. Purdie ◽  
H.F. Sewell ◽  
L. Wilkinson ◽  
B. Angus ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Oestrogen Receptor ◽  
Receptor Protein ◽  
Breast Cancers ◽  
Human Breast ◽  
Immunohistochemical Assessment

scholarly journals High level expression of differentially localized BAG-1 isoforms in some oestrogen receptor-positive human breast cancers

1999 ◽  
Vol 81 (6) ◽  
pp. 1042-1051 ◽  
Author(s):  
M Brimmell ◽  
J S Burns ◽  
P Munson ◽  
L McDonald ◽  
M J O’Hare ◽  
...  
Keyword(s):  
Oestrogen Receptor ◽  
Breast Cancers ◽  
Human Breast ◽  
High Level Expression ◽  
High Level

Bispecific monoclonal antibody therapy (anti HER-2/neu × anti CD 64) for human breast cancers that overexpress HER-2/neu

1993 ◽  
Vol 53 (S17G) ◽  
pp. 255-256
Author(s):  
Frank H. Valone ◽  
Peter A. Kaufman ◽  
Michael W. Fanger ◽  
Paul M. Guyre ◽  
Clark Springgate
Keyword(s):  
Monoclonal Antibody ◽  
Antibody Therapy ◽  
Monoclonal Antibody Therapy ◽  
Breast Cancers ◽  
Human Breast ◽  
Bispecific Monoclonal Antibody ◽  
Her 2

Breast cancers with extremely high oestrogen receptor protein status

2007 ◽  
Vol 16 (2) ◽  
pp. 125-132 ◽  
Author(s):  
S.S. WONG ◽  
N.N. KERNOHAN ◽  
F. WALKER
Keyword(s):  
Oestrogen Receptor ◽  
Receptor Protein ◽  
Breast Cancers ◽  
Protein Status

scholarly journals Combined Inhibition of PI3K, mTOR and Bcl-2 Significantly Radiosensitises Progesterone and Oestrogen Receptor Negative Breast Cancer Cells

2017 ◽  
Vol 2 (1) ◽  
Author(s):  
Roswita Hamunyela ◽  
Mogammad Hamid ◽  
Antonio Serafin ◽  
John Akudugu
Keyword(s):  
Breast Cancer ◽  
Cell Lines ◽  
Oestrogen Receptor ◽  
Triple Negative ◽  
Receptor Expression ◽  
Breast Cancers ◽  
Human Breast ◽  
Cancer Management ◽  
Breast Cell Lines ◽  
Human Breast Cell

Patients with triple-negative breast cancers (TNBC) constitute about one-fifth of all breast cancer patients. TNBC is an aggressive and heterogeneous disease entity in comparison with other types of breast cancer and, therefore, tends to be  resistant to existing treatment regimens, such as, targeted and hormone therapies. There is evidence to suggest that proliferative and survival pathways of triple-negative tumours are still poorly understood, which could be the reason for the  observed treatment resistance. Novel treatment approaches are, therefore, needed to overcome the challenges in the treatment of triple-negative breast cancers. Three human breast cell lines (MDAMB- 231, MCF-7 and MCF-12A) were pre-treated  ith inhibitors of phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR), and the pro-survival gene (Bcl-2), and their radiosensitivities were evaluated using the clonogenic cell survival assay. Inhibition of PI3K, mTOR,  and Bcl-2 with a cocktail of small molecule inhibitors NVP-BEZ235 and ABT-263 resulted in a 4- to 14-fold radiosensitisation of human breast cell lines with features similar to those of triple-negative cancers. These findings suggest that inhibition of  I3K, mTOR, and Bcl-2 can significantly enhance the sensitivity of breast cells devoid of progesterone and oestrogen receptor expression. This approach may have therapeutic potential for breast cancer management.

Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67

1991 ◽  
Vol 18 (3) ◽  
pp. 149-154 ◽  
Author(s):  
W. Weikel ◽  
T. Beck ◽  
M. Mitze ◽  
P. G. Knapstein
Keyword(s):  
Monoclonal Antibody ◽  
Breast Cancers ◽  
Human Breast ◽  
Ki 67

scholarly journals MRCKα Is Dispensable for Breast Cancer Development in the MMTV-PyMT Model

Cells ◽  
2021 ◽  
Vol 10 (4) ◽  
pp. 942
Author(s):  
Mei Qi Kwa ◽  
Rafael Brandao ◽  
Trong H. Phung ◽  
Jianfeng Ge ◽  
Giuseppe Scieri ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression Signature ◽  
Genomic Analysis ◽  
Cancer Development ◽  
Breast Cancer Cell Lines ◽  
Normal Mammary Gland ◽  
Breast Cancers ◽  
Human Breast ◽  
Breast Cancer Development

MRCKα is a ubiquitously expressed serine/threonine kinase involved in cell contraction and F-actin turnover, which is highly amplified in human breast cancer and part of a gene expression signature for bad prognosis. Nothing is known about the in vivo function of MRCKα. To explore MRCKα function in development and in breast cancer, we generated mice lacking a functional MRCKα gene. Mice were born close to the Mendelian ratio and showed no obvious phenotype including a normal mammary gland formation. Assessing breast cancer development using the transgenic MMTV-PyMT mouse model, loss of MRCKα did not affect tumor onset, tumor growth and metastasis formation. Deleting MRCKα and its related family member MRCKβ in two triple-negative breast cancer cell lines resulted in reduced invasion of MDA-MB-231 cells, but did not affect migration of 4T1 cells. Further genomic analysis of human breast cancers revealed that MRCKα is frequently co-amplified with the oncogenes ARID4B and AKT3 which might contribute to the prognostic value of MRCKα expression. Collectively, these data suggest that MRCKα might be a prognostic marker for breast cancer, but probably of limited functional importance.

Analysis of the aromatase cytochrome P450 gene in human breast cancers

1994 ◽  
Vol 13 (3) ◽  
pp. 331-337 ◽  
Author(s):  
P Sourdaine ◽  
M G Parker ◽  
J Telford ◽  
W R Miller
Keyword(s):  
Cytochrome P450 ◽  
Breast Cancers ◽  
Human Breast ◽  
Cytochrome P450 Gene ◽  
P450 Gene
Sign in / Sign up

Export Citation Format

Share Document